3-benzyloxy-1-methyl-5-nitro-1H-indazole | 507233-48-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 3-benzyloxy-1-methyl-5-nitro-1H-indazole
• 英文别名: 1-Methyl-5-nitro-3-phenylmethoxyindazole
• CAS: 507233-48-9
• 化学式: C₁₅H₁₃N₃O₃
• 分子量: 283.287
• InChiKey: BQCWOHQTZPBHFI-UHFFFAOYSA-N

物化性质

• 沸点：
  472.2±30.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  溴甲苯 、 1-methyl-5-nitro-1H-indazol-3-ol 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 5.0h， 以79%的产率得到3-benzyloxy-1-methyl-5-nitro-1H-indazole
  参考文献：
  名称：

  New perspectives on the synthesis and antichagasic activity of 3-alkoxy-1-alkyl-5-nitroindazoles

  摘要：

  The synthesis and antiprotozoal activity of some 3-alkoxy-1-alkyl- (1,4) and 3-alkoxy-1-(omega-aminoalkyl)-5-nitroindazoles (2, 3, 5-8) against different morphological forms of Trypanosoma cruzi are reported. These compounds were prepared using simple alkylation reactions and, usually, taking advantage of the reactivity of some indazole-derived betaines previously studied by us. Most indazole derivatives showed in vitro activities similar or higher than those of the reference drug benznidazole; this fact, along with low unspecific cytotoxicities against Vero cells shown by some of them, led to very good selectivity indexes (SI). The high efficiency of 5-nitroindazoles 1 and 2 against T cruzi was confirmed by further in vitro studies on infection rates and by an additional in vivo study in a murine model of acute and chronic Chagas disease. Complementary analyses of the changes in the metabolites excreted by the parasite and on the ultrastructural alterations induced after treatment with indazole derivatives 1 and 2 were also conducted. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.12.025

文献信息

• [EN] NOVEL ANTIMICROBIAL RESISTANCE BLOCKING COMPOSITIONS<br/>[FR] NOUVELLES COMPOSITIONS BLOQUANT LA RESISTANCE ANTIMICROBIENNE
  申请人：ETHICON INC

  公开号：WO2003028762A1

  公开（公告）日：2003-04-10

  This invention is concerned with antimicrobial compositions that control or prevent resistance to antimirobial effectiveness, more particularly to combinations of topical antimicrobial agents with antimutagenic or antioxidant agents that block intrinsic or acquired bacterial resistance.